CVS will add Zepbound coverage on Oct. 1, and start covering Lilly's newly approved Foundayo pill on June 1.

The top pharmacy benefit manager (PBM) in the U.S., CVS Caremark, will restore coverage to obesity products from Eli Lilly, ...

By Sriparna Roy May 28 (Reuters) - CVS Health will restore Eli Lilly's weight-loss injection Zepbound to its list of covered ...

The pharmacy benefit manager dropped Zepbound a year ago in favor of rival Wegovy — now both Lilly and Novo Nordisk drugs ...

CVS Caremark, one of America’s most powerful pharmacy benefit managers, will begin covering more GLP-1 medications again ...

CVS Health’s decision to expand formulary coverage for key GLP-1 therapies marks a boost for Eli Lilly's obesity drug ...

Eli Lilly (LLY) stock is in focus as CVS Health (CVS) restores Zepbound coverage effective Oct 1, 2026, and adds Foundayo to ...

Zepbound’s return as a preferred option reverses a prior formulary exclusion that maintained Wegovy coverage, underscoring how net pricing and rebate contracting drive PBM obesity access decisions.

In today’s Pharmaceutical Executive Daily, an FDA advisory committee weighs recommendations for the composition of the 2026–2027 Covid-19 vaccines, CVS Health restores coverage for Eli Lilly’s ...

CVS Caremark is putting Eli Lilly’s obesity drug Zepbound back on some commercial formularies starting Oct. 1, reversing a mid-2025 decision that had nudged many patients toward rival GLP-1 ...

CVS Health has announced a significant expansion of its coverage for Eli Lilly's weight-loss medications, confirming it will ...